{"id":"W2910542347","doi":"10.1182/blood-2018-99-110543","title":"Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Bosutinib; Medicine; Imatinib; Adverse effect; Internal medicine; Tyrosine-kinase inhibitor; Population; Tolerability; Oncology; Myeloid leukemia; Pharmacology; Nilotinib; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005668637,0.0006870875,0.001524168,0.0002492453,0.0003675845,0.0009015614,0.000586575,0.0008400384,0.002356003],"category_scores_gemma":[0.00338626,0.0002660656,0.002115538,0.0004605963,0.000464,0.0008780994,0.0005006672,0.001748959,0.0004098897],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00077793,"about_ca_system_score_gemma":0.0009734866,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005958891,"about_ca_topic_score_gemma":0.001707373,"domain_scores_codex":[0.9974772,0.001501736,0.0001872254,0.0003333257,0.0003097526,0.0001906561],"domain_scores_gemma":[0.9959281,0.0009863966,0.001916021,0.0003726488,0.0002331912,0.0005637206],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8161966,0.00709802,0.08770613,0.0007723013,0.006768209,0.0002093448,0.0001663499,0.001852284,0.007454037,0.0002908217,0.00439785,0.06708805],"study_design_scores_gemma":[0.3228984,0.2130845,0.4414196,0.0001881482,0.004853902,0.001255234,0.0001217256,0.003345914,0.002330638,0.0006016284,0.009758288,0.0001418796],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991257,0.003168786,0.0003640914,0.0002768093,0.0000477611,0.0006161751,0.002451892,0.00003538914,0.001782112],"genre_scores_gemma":[0.9907174,0.0008377792,0.0005702793,0.0006964051,0.0001280915,0.000651422,0.005839083,0.00001257989,0.0005470929],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005668637,"threshold_uncertainty_score":0.02997899,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01273656362391052,"score_gpt":0.2805123147050226,"score_spread":0.2677757510811121,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}